Exploring the Potential Health Benefits of CBG: How It Differs from CBD
Chemical Structure and Effects on the Body
Potential Health Benefits of CBG
- Pain-relieving properties: CBG and its constituents (CBGa) inhibit COX-1/2 enzyme activity and exhibit strong activation of TRP-vanilloid receptors, which regulate sensation and pain [5,6].
- Anti-inflammatory properties: CBG may be useful for joint and muscle soreness, inflammatory bowel issues and more [2,7,8].
- Neuro-protective properties: CBG may help protect the brain and nervous system from damage [2,9,10].
- Anti-bacterial properties: CBG may be useful for aiding with bacterial challenges [2,11].
- Appetite-stimulating properties: CBG may be useful for individuals with a loss of appetite [12]. CBG may be a good non-intoxicating alternative for those who prefer not to take a THC product for appetite stimulation.
- Skin health support: While both CBG and CBD have shown to modulate several key genes for skin aging, hydration, and inflammation, CBG selectively targets more skin genes than CBD, such as collagen, elastin and hydration [7,13,14]. Read a blog about how CBG can be used topically to support clear skin, dermatitis and more.
- Mood-enhancing properties: CBG’s activity is thought to be much like that of anandamide. Anandamide is also called the “bliss molecule” for its role in enhancing pleasure and happiness [2].
Learn More
References
1. Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009). 5-HT1areceptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. British Journal of Pharmacology, 156(1), 181–188.
2. Nachnani, R., Raup-Konsavage, W. M., & Vrana, K. E. (2020). The pharmacological case for Cannabigerol. Journal of Pharmacology and Experimental Therapeutics, 376(2), 204–212.
3. Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-Santisteban R, Sánchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, Canela EI, Borea PA, Nadal X, Franco R. Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Front Pharmacol. 2018 Jun 21;9:632.
4. Cascio, M. G., Gauson, L. A., Stevenson, L. A., Ross, R. A., & Pertwee, R. G. (2009). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129–141.
5. Ruhaak, L. R., Felth, J., Karlsson, P. C., Rafter, J. J., Verpoorte, R., & Bohlin, L. (2011). Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis Sativa. Biological and Pharmaceutical Bulletin, 34(5), 774–778.
6. Muller, C., Morales, P., & Reggio, P. H. (2019). Cannabinoid ligands targeting TRP channels. Frontiers in Molecular Neuroscience, 11.
7. Perez, E., Fernandez, J. R., Fitzgerald, C., Rouzard, K., Tamura, M., & Savile, C. (2022). In vitro and clinical evaluation of Cannabigerol (CBG) produced via yeast biosynthesis: A cannabinoid with a broad range of anti-inflammatory and skin health-boosting properties. Molecules, 27(2), 491.
8. Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., Orlando, P., Battista, G., Pagano, E., Di Marzo, V., & Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316.
9. Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2014). Neuroprotective properties of Cannabigerol in Huntington’s disease: Studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185–199.
10. Calapai, F., Cardia, L., Esposito, E., Ammendolia, I., Mondello, C., Lo Giudice, R., Gangemi, S., Calapai, G., & Mannucci, C. (2022). Pharmacological aspects and biological effects of Cannabigerol and its synthetic derivatives. Evidence-Based Complementary and Alternative Medicine, 2022, 1–14.
11. Aqawi, M., Sionov, R. V., Gallily, R., Friedman, M., & Steinberg, D. (2021). Anti-bacterial properties of Cannabigerol toward streptococcus mutans. Frontiers in Microbiology, 12.
12. Brierley, D. I., Samuels, J., Duncan, M., Whalley, B. J., & Williams, C. M. (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology, 233(19-20), 3603–3613.
13. Luz-Veiga, M., Amorim, M., Pinto-Ribeiro, I., Oliveira, A. L., Silva, S., Pimentel, L. L., Rodríguez-Alcalá, L. M., Madureira, R., Pintado, M., Azevedo-Silva, J., & Fernandes, J. (2023). Cannabidiol and cannabigerol exert antimicrobial activity without compromising skin microbiota. International Journal of Molecular Sciences, 24(3), 2389.
14. Zagórska-Dziok, M., Bujak, T., Ziemlewska, A., & Nizio?-?ukaszewska, Z. (2021). Positive effect of cannabis sativa L. Herb extracts on skin cells and assessment of cannabinoid-based Hydrogels Properties. Molecules, 26(4), 802.
15. Russo, E. B. (2019). The case for the entourage effect and conventional breeding of clinical cannabis: No “strain,” no gain. Frontiers in Plant Science, 9.
16. https://www.medrxiv.org/content/10.1101/2023.03.13.23287212v1
17. Mammana, S., Cavalli, E., Gugliandolo, A., Silvestro, S., Pollastro, F., Bramanti, P., & Mazzon, E. (2019). Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? effectiveness of cannabidiol associated with Cannabigerol. Medicina, 55(11), 747.
*These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease. This information is presented for educational purposes only and was developed to provide health professionals with an understanding of the potential applications of cannabinoids.